Navigation Links
New FDA Approved Drug To Treat Migraine

Axert has been approved by the FDA for the acute treatment of migraine with or without aura in adults.

Axert belongs to a class of drugs known as selective serotonin receptor agonists.Axert tablets contain almotriptan malate, a selective 5-hydroxytryptamine receptor agonist.//

This drug targets serotonin receptors and act against migraine headaches by inducing the constriction of blood vessels surrounding the brain.

Nausea, sleepiness, numbness, dry mouth and headache are the side effects associated with the use of Axert. In controlled trials, Axert showed a low percentage of side effects.

However this class of compounds has the potential to cause coronary vasospasm, and as a result Axert is not advised for patients with ischemic or vasospastic artery disease.

This drug is introduced by the pharmaceutical company, Pharmacia. Results of controlled clinical trials demonstrated that Axert was highly effective and well tolerated.

Axert is now an exciting new migraine therapy from Pharmacia, proven effective in the acute treatment of migraine.


Page: 1

Related medicine news :

1. Levothyroxine Thyroid Hormone Replacement, Approved for Hypothyroidism
2. New FDA Approved Drug NATRECOR For Heart Failure Patients
3. New Oral Rinse For Gingivitis Approved By FDA
4. Child Friendly Zidovudine Preparation for treating HIV infection Approved By The FDA
5. AIDS Generic Drugs Approved by FDA for Sale in US
6. FDA Approved Nerve-Stimulation Therapy Now Available In New York
7. Revlimid Approved For Treatment Of Myelodysplastic Syndrome (MDS) by FDA
8. Pfizer’s Eraxis Approved By The FD
9. Inhalers for Kids Was Approved By the FDA
10. Alcoholism Drug Vivitrol Approved By FDA
11. Drug Approved to Curb Alcohol Dependency
Post Your Comments:

(Date:6/26/2016)... ... ... On June 10-11, 2016, A Forever Recovery, a holistic treatment center for ... Table in Battle Creek, MI, where the rehabilitation facility is located. This annual celebration ... world’s leading providers of cereal and other breakfast foods. Its residents often refer to ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released today, ... their residents by lacking a comprehensive, proven plan to eliminate prescription ... definitive ranking of how states are tackling the worst drug crisis ... four states – Kentucky , New ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: